Error
Your session has expired. Please click "Refresh" to refresh the page.
Nuclear Receptor Signaling Atlas
A research resource for the nuclear receptor signaling community
Newsletter Sign Up
PPARG
Overview
Synonyms
ARF6 ; CIMT1 ; GLM1 ; NR1C3 ; Nr1c3 ; PPAR gamma ; PPAR-GAMMA ; PPAR-gamma ; PPAR-gamma2 ; PPARG ; PPARG1 ; PPARG2 ; PPARGAMMA ; PPAR[g] ; PPARgamma ; PPARgamma2 ; Pparg ; nuclear receptor subfamily 1 group C member 3 ; peroxisome proliferative activated receptor gamma ; peroxisome proliferative activated receptor, gamma ; peroxisome proliferator activated receptor gamma ; peroxisome proliferator activated receptor gamma 2 ; peroxisome proliferator activated receptor gamma 4 ; peroxisome proliferator activator receptor, gamma ; peroxisome proliferator-activated nuclear receptor gamma variant 1 more...
Synonyms
ARF6; CIMT1; GLM1; NR1C3; Nr1c3; PPAR gamma; PPAR-GAMMA; PPAR-gamma; PPAR-gamma2; PPARG; PPARG1; PPARG2; PPARGAMMA; PPAR[g]; PPARgamma; PPARgamma2; Pparg; nuclear receptor subfamily 1 group C member 3; peroxisome proliferative activated receptor gamma; peroxisome proliferative activated receptor, gamma; peroxisome proliferator activated receptor gamma; peroxisome proliferator activated receptor gamma 2; peroxisome proliferator activated receptor gamma 4; peroxisome proliferator activator receptor, gamma; peroxisome proliferator-activated nuclear receptor gamma variant 1; peroxisome proliferator-activated receptor gamma; peroxisome proliferator-activated receptor gamma 1; peroxisome proliferator-activated receptor gamma 1-a; peroxisome proliferator-activated receptor gamma 1-b; pparg
NURSA Name
Peroxisome proliferator activated receptor γ
Official Symbol
PPARG
No records found.
Description
PPAR-γ is a fatty acid-activated member of the PPAR subfamily of the nuclear receptor superfamily of transcription factors. Collectively the PPAR subfamily plays important roles in lipid and glucose metabolism, and has been implicated in obesity-related metabolic diseases such as hyperlipidemia, insulin resistance, and coronary artery disease. PPAR-γ is expressed at low levels in most physiological systems, including the central nervous system (CNS), endocrine system, gastrointestinal system, reproductive system, cardiopulmonary system and metabolic tissues, but is most highly expressed in brown and white adipose tissue. PPAR-γ dysfunction is associated with susceptibility to glioblastoma, familial partial lipodystrophy, atherosclerosis, hypertriglyceridemia, myocardial infarct, severe obesity, essential hypertension, insulin resistance and diabetes II diabetes, diabetic nephropathy, colon cancer, bladder cancer, breast cancer, lung cancer, non-Hodgkin's lymphoma, prostate cancer and skin cancer. Susceptibility to psoriasis, Alzheimer's disease and preterm delivery has also been observed. Targeted disruption (knockout) of the PPAR-γ gene leads to defects in embryogenesis, brown and white adipose tissue, the liver and biliary system, the cardiovascular system, the digestive system, homeostasis and metabolism, muscle, hearing, the renal and urinary system and prenatal and perinatal lethality.
Original References:
Elbrecht A, Chen Y, Cullinan CA, Hayes N, Leibowitz Md, Moller DE and Berger J (1996) Molecular cloning, expression and characterization of human peroxisome proliferator activated receptors gamma 1 and gamma 2. Biochem. Biophys. Res. Commun. 224 431-7 View Abstract | View PubMed
Mukherjee R, Jow L, Croston GE and Paterniti JR (1997) Identification, characterization, and tissue distribution of human peroxisome proliferator-activated receptor (PPAR) isoforms PPARgamma2 versus PPARgamma1 and activation with retinoid X receptor agonists and antagonists. J. Biol. Chem. 16 8071-6 View Abstract | View PubMed
Dreyer C, Krey G, Keller H, Givel F, Helftenbein G and Wahli W (1992) Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. Cell 68 879-87 View Abstract | View PubMed
Ortholog
Gene
RNA
Protein
GO Terms
Crystal Structures
Post-Translational Modifications
Protein-Protein Interactions
Targeting miRNAs
Pathways
Pharmacogenomics
Datasets
Reagents
Diseases
Clinical Trials
Animal Models
Ligands
Drugs
Literature